Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs

Amgen first entered Ohio in June 2021, when it announced plans to invest in a state-of-the-art biomanufacturing facility in Central Ohio. This investment marked the company’s expansion into the Columbus Region, which enhanced its U.S.-based manufacturing capabilities and created 400 jobs upon the facility’s opening.

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

The smart facility, will rely on artificial intelligence and automation, across three areas: advanced industrial automation using robotics and equipment automation; digital quality for automated inspection, testing and real time release of manufactured batches; and data availability to monitor and manage process and operational performance.

The site will employ highly automated storage and retrieval systems, automated guided vehicles to ferry materials, and collaborative robots.